Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate compared with dual therapy for the treatment of chronic obstructive pulmonary disease (COPD) in Canada

References

• Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med. 2023;207(7):819–837. doi:10.1164/rccm.202301-0106PP.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/s0140-6736(07)61382-8.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Magnussen H, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19(1):251. doi:10.1186/s12931-018-0944-3.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019/10/02 2019;3(4):210–232. doi:10.1080/24745332.2019.1668652.
   Web of Science ®Google Scholar
• Hurst JR, Siddiqui MK, Singh B, Varghese P, Holmgren U, de Nigris E. A systematic literature review of the humanistic burden of COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:1303–1314. doi:10.2147/copd.S296696.
   PubMed Web of Science ®Google Scholar
• Michalovic E, Jensen D, Dandurand RJ, et al. Description of participation in daily and social activities for individuals with COPD. COPD. 2020;17(5):543–556. doi:10.1080/15412555.2020.1798373.
   PubMedGoogle Scholar
• Dang-Tan T, Ismaila A, Zhang S, Zarotsky V, Bernauer M. Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review. BMC Res Notes. 2015;8(1):464. doi:10.1186/s13104-015-1427-y.
   PubMedGoogle Scholar
• Flegel K, Stanbrook MB. To keep patients with COPD out of hospital, look beyond the lungs. CMAJ. 2018;190(48):E1402–e1403. doi:10.1503/cmaj.181462.
   PubMed Web of Science ®Google Scholar
• Johnston K, Qian C, Soliman M, Noorduyn S, Penz E. Treatment patterns of patients with chronic obstructive pulmonary disease (COPD) in Ontario, Canada. Eur Respir J. 2021;58(suppl 65):PA2414. doi:10.1183/13993003.congress-2021.PA2414.
   Google Scholar
• Fernández Tena A, Casan Clarà P. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012;48(7):240–246. doi:10.1016/j.arbres.2012.02.003.
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Noga B, Vehring R, Cummings RH, Dwivedi SK. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3(13):1703–1718. doi:10.4155/fmc.11.133.
   PubMed Web of Science ®Google Scholar
• Taylor G, Warren S, Dwivedi S, et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;111:450–457. doi:10.1016/j.ejps.2017.10.026.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/s2213-2600(18)30327-8.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021;185:106509. doi:10.1016/j.rmed.2021.106509.
   PubMed Web of Science ®Google Scholar
• Halpin DM. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(3):227–233. doi:10.1513/pats.200507-072SF.
   PubMedGoogle Scholar
• Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. In: Handbooks in health economic evaluation series. Oxford: Oxford University Press; 2011.
   Google Scholar
• Neumann PJ, Willke RJ, Garrison LP, Jr. A health economics approach to US value assessment frameworks-introduction: An ISPOR special task force report [1]. Value Health. 2018;21(2):119–123. doi:10.1016/j.jval.2017.12.012.
   PubMed Web of Science ®Google Scholar
• Canadian Chronic Disease Surveillance System. Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Canada, 2018. https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/asthma-chronic-obstructive-pulmonary-disease-canada-2018/pub-eng.pdf.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada - 4th Edition. 2017. https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition.
   Google Scholar
• de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J. Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: United Kingdom analysis using the ETHOS study. Int J Chron Obstruct Pulmon Dis. 2022;17:2987–3000. doi:10.2147/copd.S381138.
   PubMed Web of Science ®Google Scholar
• Anley G, Shah D, Schroeder M, et al. P249 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus dual bronchodilator therapy (UMEC/VI) in patients with COPD – cost-effectiveness in the UK. Thorax. 2018;73(Suppl 4.):A236–A237. doi:10.1136/thorax-2018-212555.405.
   Google Scholar
• Martin A, Shah D, Schroeder M, et al. P250 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with COPD – cost-effectiveness in the UK. Thorax. 2018;73(Suppl 4):A237. doi:10.1136/thorax-2018-212555.406.
   Google Scholar
• Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis. 2009;4:137–148. doi:10.2147/copd.s5237.
   PubMedGoogle Scholar
• Nie JX, Wang L, Upshur RE. Mortality of elderly patients in Ontario after hospital admission for chronic obstructive pulmonary disease. Can Respir J. 2007;14(8):485–489. doi:10.1155/2007/425248.
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians. COPD: Who cares when it matters most? - National Supplementary Report: February 2017. 2017. https://www.rcplondon.ac.uk/projects/outputs/copd-who-cares-when-it-matters-most-outcomes-report-2014. Accessed January 12, 2021.
   Google Scholar
• Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006;130(4):1117–1128. doi:10.1378/chest.130.4.1117.
   PubMed Web of Science ®Google Scholar
• IQVIA. ODB RxDyanmics database. 2017. – Indication adjustment – see QC. Ontario, Canada; 2021.
   Google Scholar
• IQVIA. PharmaStat database. Historical public claims, cost, units, and days data for ICS/LABAs and LAMAs. Q3 2019 to Q2 2020 – see QC. Ontario, Canada; 2021.
   Google Scholar
• Ontario Ministry of Health. Ontario drug benefit formulary/comparative drug index. https://www.formulary.health.gov.on.ca/formulary/.
   Google Scholar
• Ontario Ministry of Health. Schedule of benefits - physician services under the health Insurance Act. 2020. https://www.health.gov.on.ca/en/pro/programs/ohip/sob/.
   Google Scholar
• Ontario Ministry of Health. Ontario case cost costing analysis tool. https://hsimi.ca/occp/occpreports/. Accessed November 8, 2021.
   Google Scholar
• IQVIA. PharmaStat database. Historical public claims, cost, units, and days data for Trelegy Ellipta, ICS/LABAs, and LAMAs. Q3 2015 to Q2 2020. Ontario, Canada; 2020.
   Google Scholar
• Noorduyn S, Soliman M, Qian C, Johnston K, Penz E. Exacerbations in chronic obstructive pulmonary disease (COPD) in Ontario, Canada. Eur Respir J. 2021;58(suppl 65):OA4063. doi: 10.1183/13993003.congress-2021.OA4063.
   Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7(1):00480-2020. doi:10.1183/23120541.00480-2020.
   PubMedGoogle Scholar
• Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: The IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695. doi:10.2147/copd.S216072.
   PubMed Web of Science ®Google Scholar
• Martin A, Shah D, Ndirangu K, et al. Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Res. 2022;8(1):00333-2021. doi:10.1183/23120541.00333-2021.
   PubMedGoogle Scholar
• Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with Chronic Obstructive Pulmonary Disease (COPD) using the FULFIL trial: A Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632. doi:10.2147/copd.S240556.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Molinari N, Ferguson GT, et al. Efficacy and safety of budesonide/glycopyrronium/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta-analysis. Adv Ther. 2021/06/01 2021;38(6):3089–3112. doi:10.1007/s12325-021-01703-z.
   PubMed Web of Science ®Google Scholar
• Reimbursement Team. Budesonide/glycopyrronium/formoterol fumarate dihydrate (breztri aerosphere). Can J Health Technol. 2021;1(9).
   Google Scholar